Avalo Therapeutics (AVTX) Stock: Buy, Sell, or Hold?
AVTX - Avalo Therapeutics, Inc. Common Stock
$16.18
0.06 (0.37%)
▲
5d:
-15.86%
30d:
-16.81%
90d:
+9.62%
WAIT
LOW Confidence
Analysis Updated: Sep 14, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When AVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AVTX is down 15.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AVTX is down 15.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AVTX is currently trading at $16.18, which is considered oversold relative to its 30-day fair value range of $18.25 to $20.13.
Technical Outlook: Technically, AVTX is in a uptrend. The price is currently testing key support at $16.02. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $44.08 (+172.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AVTX is in a uptrend. The price is currently testing key support at $16.02. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $44.08 (+172.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$18.25 -
$20.13
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 172.5% below Wall St target ($44.08)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$18.25 -
$20.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$16.02
Resistance Level
$20.49
Current Trend
Uptrend
Technical data as of
Sep 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.90
Wall Street Target
$44.08
(+172.5%)
Revenue Growth (YoY)
-69.3%
Share & Embed Analysis
Last updated: September 15, 2026 5:00 AM ET
Data refreshes hourly during market hours. Next update: 6:00 AM
Data refreshes hourly during market hours. Next update: 6:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Mittie Doyle
SELL
3970 shares
2026-04-06
Christopher Ryan Sullivan
SELL
7980 shares
2026-04-02
Christopher Ryan Sullivan
SELL
7979 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 49 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 37 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$140 | 63 BUY |
